目的:探讨纳洛酮治疗慢性阻塞性肺病并发肺性脑病的临床疗效.方法:将76例肺性脑病患者随机分成治疗组和对照组,治疗组38例患者,给予纳洛酮首次0.4 mg 加生理盐水20 ml 静脉注射;然后纳洛酮0.8～2.0 mg+5%葡萄糖 500 ml 静脉滴注,1次/d;对照组38例患者给予尼可刹米1.5～2.25 g+5%葡萄糖500 ml 静脉滴注,1次/d,观察疗效3 d.结果:治疗组30 min～3 d内患者血气指标大多数转为正常,患者的神志意识障碍得到了明显改善,有效率为94.74%,尼可刹米对照组有效率为76.31%,治疗组的有效率显著高于对照组,差异有统计学意义(P＜0.05);纳洛酮应用期间无毒副作用发生.结论:纳洛酮治疗肺性脑病安全、经济、疗效确切.%Objective: To investigate clinical efficacy of Naloxone in treatment of chronic obstructive pulmonary disease (COPD) complicated by pulmonary encephalopathy. Methods: 76 cases of pulmonary encephalopathy patients were randomly divided into treatment group (38 cases) and control group (38 cases), treatment group was given Naloxone 0.4 mg + 20 ml saline first iv, and 0.8~2.0 mg+5% glucose 500 ml v gtt qd, control group was given Nikethamide 1.5-2.25 g+5% glucose 500 ml ivgtt qd. The effect was observed for 3 days. Results: The blood gas of Naloxone group changed to normal in 30 minutes to 3 days, the patient's consciousness improved significantly, the efficiency rate of treatment group (94.74%) was significantly higher than that of control group (76.31%), the difference was significant (P<0.05); there was no toxic side effects during the application of Naloxone. Conclusion: It is security, economic and effective of Naloxone in treatment of pulmonary encephalopathy.
展开▼
